FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220992037> ?p ?o ?g. }

• W4220992037 endingPage "175883592210839" @default.
• W4220992037 startingPage "175883592210839" @default.
• W4220992037 abstract "For estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC), the current standard first-line treatment includes an aromatase inhibitor in combination with a cyclin-dependent kinase 4/6 inhibitor. When resistance occurs, often related to the occurrence of ESR1 mutations, selective estrogen receptor modulators or degraders (SERDs) may be used, alone or in combination regimens. Amcenestrant (SAR439859), an optimized oral SERD, has shown clinical antitumor activity in combination with palbociclib in patients with ER+/HER2- ABC and, as monotherapy, in patients with and without ESR1 mutations. Here, we describe the study design of AMEERA-5, an ongoing, prospective, phase 3, randomized, double-blind, multinational study comparing the efficacy and safety of amcenestrant plus palbociclib versus letrozole plus palbociclib in patients with advanced (locoregional recurrent or metastatic) ER+/HER2- breast cancer.Patients are pre-/postmenopausal women and men with no prior systemic therapy for ABC. The planned enrollment is 1066 patients. Patients are randomized 1:1 to either amcenestrant 200 mg plus palbociclib 125 mg or letrozole 2.5 mg plus palbociclib 125 mg. Amcenestrant, letrozole, and their matching placebos are taken once daily continuously; palbociclib is taken once daily for 21 days, followed by 7 days off-treatment for a 28-day cycle. Treatment continues until disease progression, unacceptable toxicity, or decision to stop treatment. Pre-/perimenopausal women and men receive goserelin subcutaneously. Randomization is stratified by de novo metastatic disease, menopausal status, and visceral metastases. The primary endpoint is progression-free survival. The key secondary endpoint is overall survival; others are safety, pharmacokinetics, and quality of life.AMEERA-5 is evaluating the efficacy and safety of amcenestrant in combination with palbociclib as first-line therapy in pre-/postmenopausal women and men with ER+/HER2- ABC.NCT04478266." @default.
• W4220992037 created "2022-04-03" @default.
• W4220992037 creator A5004188539 @default.
• W4220992037 creator A5008549101 @default.
• W4220992037 creator A5033987639 @default.
• W4220992037 creator A5034972183 @default.
• W4220992037 creator A5037865295 @default.
• W4220992037 creator A5068059897 @default.
• W4220992037 creator A5071432873 @default.
• W4220992037 creator A5073540330 @default.
• W4220992037 creator A5073655713 @default.
• W4220992037 creator A5079128498 @default.
• W4220992037 creator A5083142899 @default.
• W4220992037 creator A5091087835 @default.
• W4220992037 date "2022-01-01" @default.
• W4220992037 modified "2023-10-18" @default.
• W4220992037 title "AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib<i>versus</i>letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer" @default.
• W4220992037 cites W2019607817 @default.
• W4220992037 cites W2290950904 @default.
• W4220992037 cites W2528767298 @default.
• W4220992037 cites W2552099557 @default.
• W4220992037 cites W2558360748 @default.
• W4220992037 cites W2560635244 @default.
• W4220992037 cites W2620993107 @default.
• W4220992037 cites W2719623628 @default.
• W4220992037 cites W2777085303 @default.
• W4220992037 cites W2783457746 @default.
• W4220992037 cites W2802776309 @default.
• W4220992037 cites W2804105316 @default.
• W4220992037 cites W2805575723 @default.
• W4220992037 cites W2910023631 @default.
• W4220992037 cites W2910972034 @default.
• W4220992037 cites W2948069739 @default.
• W4220992037 cites W2995321507 @default.
• W4220992037 cites W3010197652 @default.
• W4220992037 cites W3010575887 @default.
• W4220992037 cites W3015634062 @default.
• W4220992037 cites W3031130887 @default.
• W4220992037 cites W3083626914 @default.
• W4220992037 cites W3094721087 @default.
• W4220992037 cites W3095389949 @default.
• W4220992037 cites W3112130448 @default.
• W4220992037 cites W3123867938 @default.
• W4220992037 cites W3128646645 @default.
• W4220992037 cites W3131725600 @default.
• W4220992037 cites W3134027539 @default.
• W4220992037 cites W3145363169 @default.
• W4220992037 cites W3158115242 @default.
• W4220992037 cites W3170992570 @default.
• W4220992037 cites W3171075867 @default.
• W4220992037 cites W3171199698 @default.
• W4220992037 cites W3171910277 @default.
• W4220992037 cites W4206666777 @default.
• W4220992037 doi "https://doi.org/10.1177/17588359221083956" @default.
• W4220992037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35309087" @default.
• W4220992037 hasPublicationYear "2022" @default.
• W4220992037 type Work @default.
• W4220992037 citedByCount "14" @default.
• W4220992037 countsByYear W42209920372022 @default.
• W4220992037 countsByYear W42209920372023 @default.
• W4220992037 crossrefType "journal-article" @default.
• W4220992037 hasAuthorship W4220992037A5004188539 @default.
• W4220992037 hasAuthorship W4220992037A5008549101 @default.
• W4220992037 hasAuthorship W4220992037A5033987639 @default.
• W4220992037 hasAuthorship W4220992037A5034972183 @default.
• W4220992037 hasAuthorship W4220992037A5037865295 @default.
• W4220992037 hasAuthorship W4220992037A5068059897 @default.
• W4220992037 hasAuthorship W4220992037A5071432873 @default.
• W4220992037 hasAuthorship W4220992037A5073540330 @default.
• W4220992037 hasAuthorship W4220992037A5073655713 @default.
• W4220992037 hasAuthorship W4220992037A5079128498 @default.
• W4220992037 hasAuthorship W4220992037A5083142899 @default.
• W4220992037 hasAuthorship W4220992037A5091087835 @default.
• W4220992037 hasBestOaLocation W42209920371 @default.
• W4220992037 hasConcept C121608353 @default.
• W4220992037 hasConcept C126322002 @default.
• W4220992037 hasConcept C143998085 @default.
• W4220992037 hasConcept C168563851 @default.
• W4220992037 hasConcept C203092338 @default.
• W4220992037 hasConcept C2775930923 @default.
• W4220992037 hasConcept C2776067312 @default.
• W4220992037 hasConcept C2777176818 @default.
• W4220992037 hasConcept C2778504769 @default.
• W4220992037 hasConcept C2778812593 @default.
• W4220992037 hasConcept C2779744173 @default.
• W4220992037 hasConcept C2780482068 @default.
• W4220992037 hasConcept C29456083 @default.
• W4220992037 hasConcept C530470458 @default.
• W4220992037 hasConcept C71924100 @default.
• W4220992037 hasConcept C84606932 @default.
• W4220992037 hasConceptScore W4220992037C121608353 @default.
• W4220992037 hasConceptScore W4220992037C126322002 @default.
• W4220992037 hasConceptScore W4220992037C143998085 @default.
• W4220992037 hasConceptScore W4220992037C168563851 @default.
• W4220992037 hasConceptScore W4220992037C203092338 @default.
• W4220992037 hasConceptScore W4220992037C2775930923 @default.
• W4220992037 hasConceptScore W4220992037C2776067312 @default.
• W4220992037 hasConceptScore W4220992037C2777176818 @default.

• next